Pibrentasvir

Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

Product Specifications

CAS Number

[1353900-92-1]

Product Name Alternative

ABT-530

UNSPSC

12352005

Hazard Statement

H315, H317, H318, H334, H335, H341, H361, H370, H413

Target

HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Pibrentasvir.html

Purity

99.94

Solubility

DMSO : 62 mg/mL (ultrasonic; warming)

Smiles

FC(C=C(N=C([C@H](CCC1)N1C([C@H]([C@@H](C)OC)NC(OC)=O)=O)N2)C2=C3)=C3[C@@H]4N(C5=CC(F)=C(N6CCC(C7=CC=C(F)C=C7)CC6)C(F)=C5)[C@@H](C(C=C(NC([C@H](CCC8)N8C([C@H]([C@@H](C)OC)NC(OC)=O)=O)=N9)C9=C%10)=C%10F)CC4

Molecular Formula

C57H65F5N10O8

Molecular Weight

1113.18

Precautions

H315, H317, H318, H334, H335, H341, H361, H370, H413

References & Citations

[1]Ng TI, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Apr 24;61 (5) . pii: e02558-16.